AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25902552 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CHO diet (25% CHO)
Number of subjects: 19
Study 25902552 — intervention group
Group type: COMPARATOR
Intervention: Normal CHO diet (56% CHO)
Number of subjects: 19
Study 22459017 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0
Study 22459017 — intervention group
Group type: COMPARATOR
Intervention: Alert state
Number of subjects: 0
Study 20870365 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence-contingent condition (CM)
Number of subjects: 154
Study 20870365 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 154
Study 19849864 — intervention group
Group type: EXPERIMENTAL
Intervention: Coroflex Please stent
Number of subjects: 900
Study 19849864 — intervention group
Group type: COMPARATOR
Intervention: Taxus Liberte stent
Number of subjects: 900
Study 16421011 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 22
Study 16421011 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 22
Study 16421011 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 22
Study 16421011 — intervention group
Group type: COMPARATOR
Intervention: Triple antiplatelet therapy
Number of subjects: 22
Study 12927950 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg/day
Number of subjects: 0
Study 10852750 — intervention group
Group type: COMPARATOR
Intervention: 100% O(2) at resting minute ventilation (V E) for 60 min
Number of subjects: 7
Study 10852750 — intervention group
Group type: EXPERIMENTAL
Intervention: O(2) containing 4.5 to 4.8% CO(2) at 2 to 6 times resting V E for 90 min
Number of subjects: 7
Study 9089471 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (4 bolus injections of 50 micrograms GHRH)
Number of subjects: 7
Study 9089471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 1584260 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy and radiation therapy (fluorouracil 1000 mg/m² daily for 4 days and cisplatin 75 mg/m² on the first day plus 5000 cGy of radiation)
Number of subjects: 121
Study 1584260 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone (6400 cGy)
Number of subjects: 121
Study 2865677 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not receiving beta-adrenergic blocking agents
Number of subjects: 2999
Study 2865677 — intervention group
Group type: COMPARATOR
Intervention: Patients receiving beta-adrenergic blocking agents
Number of subjects: 2999
Study 30784332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ventilation with pure oxygen (Group B)
Number of subjects: 100
Study 30784332 — intervention group
Group type: COMPARATOR
Intervention: Conventional air/oxygen 1:1 mixture (Group A)
Number of subjects: 100
Study 29747966 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 49
Study 29747966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 28166067 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided femoral nerve block with 20 ml of 2% lignocaine
Number of subjects: 40
Study 28166067 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl 2 mc/kg
Number of subjects: 40
Study 28166067 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided femoral nerve block
Number of subjects: 40
Study 28166067 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl
Number of subjects: 40
Study 23826633 — intervention group
Group type: EXPERIMENTAL
Intervention: EG2 (four PE sessions/week of high intensity)
Number of subjects: 67
Study 23826633 — intervention group
Group type: EXPERIMENTAL
Intervention: EG1 (four PE sessions/week)
Number of subjects: 67
Study 23826633 — intervention group
Group type: COMPARATOR
Intervention: CG (usual PE, two sessions/week)
Number of subjects: 67
Study 21830317 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial antibiotic therapy to eradicate Pseudomonas aeruginosa (Pa) followed by 15 months of intermittent maintenance antibiotics.
Number of subjects: 282
Study 21830317 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful initial eradication of Pseudomonas aeruginosa (Pa).
Number of subjects: 282
Study 21830317 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent Pseudomonas aeruginosa (Pa) during the maintenance phase after failure to initially eradicate.
Number of subjects: 282
Study 20110697 — intervention group
Group type: EXPERIMENTAL
Intervention: MFP dentifrice (1,450 microg F/g)
Number of subjects: 1
Study 20110697 — intervention group
Group type: COMPARATOR
Intervention: Non-F dentifrice
Number of subjects: 1
Study 18320252 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1.8 g/day
Number of subjects: 12
Study 18320252 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EPA)
Number of subjects: 12
Study 11176000 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trials in neurosurgery
Number of subjects: 0
Study 10470456 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic staging of cancer
Number of subjects: 0
Study 10470456 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine use of staging in a population
Number of subjects: 0
Study 7998893 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% cream
Number of subjects: 125
Study 7998893 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 125
Study 3135392 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon gamma (IFN gamma)
Number of subjects: 26
Study 3135392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31872328 — intervention group
Group type: EXPERIMENTAL
Intervention: Vergence eye movement task (eight movements)
Number of subjects: 27
Study 28093999 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 U of C1-INH with 24,000 U of rHuPH20
Number of subjects: 41
Study 28093999 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 U of C1-INH with 48,000 U of rHuPH20
Number of subjects: 41
Study 28093999 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 41
Study 28093999 — intervention group
Group type: EXPERIMENTAL
Intervention: Study completers
Number of subjects: 41
Study 28093999 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprophylaxis users at baseline on high treatment doses
Number of subjects: 41
Study 25993547 — intervention group
Group type: EXPERIMENTAL
Intervention: ALO-02
Number of subjects: 281
Study 25993547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 23891455 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene before donning nonsterile gloves
Number of subjects: 100
Study 23891455 — intervention group
Group type: COMPARATOR
Intervention: Directly don nonsterile gloves
Number of subjects: 100
Study 21794822 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy manual techniques, 1-2 sessions per week for six months
Number of subjects: 29
Study 21794822 — intervention group
Group type: COMPARATOR
Intervention: Control group (GC)
Number of subjects: 29
Study 19262230 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8‐16 mg/day (n = 91)
Number of subjects: 196
Study 19262230 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10‐20 mg/day (n = 105)
Number of subjects: 196
Study 16353140 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemirolast (10 mg) administered orally 2 hours before paclitaxel infusion.
Number of subjects: 84
Study 16353140 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral lactose) administered 2 hours before paclitaxel infusion.
Number of subjects: 84
Study 15342830 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type A (BoNT) injections in the submandibular glands
Number of subjects: 45
Study 15342830 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine treatment
Number of subjects: 45
Study 15342830 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurements
Number of subjects: 45
Study 15342830 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments after BoNT injections
Number of subjects: 45
Study 10932998 — intervention group
Group type: EXPERIMENTAL
Intervention: New pain management standard
Number of subjects: 173
Study 9065194 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 600 mg followed by Misoprostol 400 micrograms after 48 hours
Number of subjects: 1373
Study 9065194 — intervention group
Group type: COMPARATOR
Intervention: Surgical abortion
Number of subjects: 1373
Study 8421173 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium w vaccine
Number of subjects: 56
Study 8421173 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 31253162 — intervention group
Group type: EXPERIMENTAL
Intervention: GLY/eFlow (50 μg GLY delivered by eFlow CS nebulizer)
Number of subjects: 30
Study 31253162 — intervention group
Group type: EXPERIMENTAL
Intervention: GLY/DPI (63 μg GLY delivered by dry powder inhaler)
Number of subjects: 30
Study 31253162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 50 μg GLY
Number of subjects: 30
Study 28317438 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR-guided revascularization
Number of subjects: 2037
Study 28317438 — intervention group
Group type: COMPARATOR
Intervention: FFR-guided revascularization
Number of subjects: 2037
Study 25564570 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 0
Study 25564570 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 22299818 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial laser therapy (TLT)
Number of subjects: 778
Study 22299818 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 778
Study 21981453 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity blood-flow-restricted resistance exercise (20% 1-RM)
Number of subjects: 10
Study 21981453 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise (20% 1-RM)
Number of subjects: 10
Study 21981453 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise (70% 1-RM)
Number of subjects: 10
Study 19769651 — intervention group
Group type: EXPERIMENTAL
Intervention: DRP training module
Number of subjects: 74
Study 19769651 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 74
Study 16467715 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily for 16 weeks
Number of subjects: 145
Study 16467715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 16467715 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily
Number of subjects: 145
Study 15131555 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic Truncated Exponential (BTE) shocks
Number of subjects: 72
Study 15131555 — intervention group
Group type: COMPARATOR
Intervention: Monophasic Damped Sine (MDS) shocks
Number of subjects: 72
Study 15131555 — intervention group
Group type: EXPERIMENTAL
Intervention: BTE shocks
Number of subjects: 72
Study 11516923 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational Problem‐Solving Skills (VPSS), 10 sessions
Number of subjects: 109
Study 11516923 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal Problem‐Solving (IPS), 10 sessions
Number of subjects: 109
Study 9266494 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8350289 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive coping treatment (short training in conscious use of positive self-statements)
Number of subjects: 65
Study 8350289 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous processing condition
Number of subjects: 65
Study 3726165 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 296
Study 3726165 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of parametrial infiltration
Number of subjects: 296
Study 3726165 — intervention group
Group type: COMPARATOR
Intervention: Involvement of the lower third of the vagina
Number of subjects: 296
Study 3726165 — intervention group
Group type: COMPARATOR
Intervention: Presence of bullous oedema
Number of subjects: 296
Study 3726165 — intervention group
Group type: COMPARATOR
Intervention: Histological differentiation of the disease
Number of subjects: 296
Study 30165823 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy combining omeprazole, amoxicillin and one of clarithromycin/ciprofloxacin/metronidazole
Number of subjects: 299
Study 30165823 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy combining omeprazole, amoxicillin, ciprofloxacin and doxycycline
Number of subjects: 299
Study 30165823 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole based triple therapy
Number of subjects: 299
Study 30165823 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin based combination therapies
Number of subjects: 299
Study 27569438 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC-stroke score with hs-cTnT
Number of subjects: 8356
Study 27569438 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC-stroke score with hs-cTnI
Number of subjects: 8356
Study 27569438 — intervention group
Group type: COMPARATOR
Intervention: CHA2DS2VASc score
Number of subjects: 8356
Study 27569438 — intervention group
Group type: COMPARATOR
Intervention: ATRIA score
Number of subjects: 8356
Study 24281435 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of ibuprofen (IBU) at standard doses (10/5/5 mg/kg)
Number of subjects: 112
Study 24281435 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of ibuprofen (IBU) at standard doses (10/5/5 mg/kg)
Number of subjects: 112
Study 24281435 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of ibuprofen (IBU)
Number of subjects: 112
Study 24281435 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of ibuprofen (IBU)
Number of subjects: 112
Study 22325800 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer assisted learning programme for interpreting CTG patterns
Number of subjects: 179
Study 20973707 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS) 10-30 mg/9 hours
Number of subjects: 162
Study 20973707 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS)
Number of subjects: 162
Study 18520598 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg once daily for 11 days)
Number of subjects: 17
Study 18520598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 16850317 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretch contractions at 0, 10, 30, 60, and 100% of maximal voluntary effort with steady-state isometric force controlled at 30% of MVC.
Number of subjects: 11
Study 16850317 — intervention group
Group type: COMPARATOR
Intervention: Passive muscle stretching.
Number of subjects: 11
Study 16850317 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretch contractions at maximal voluntary effort.
Number of subjects: 11
Study 11069515 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% ALA lotion
Number of subjects: 6
Study 11069515 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 10% ALA lotion
Number of subjects: 6
Study 11069515 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 20% ALA lotion
Number of subjects: 6
Study 11069515 — intervention group
Group type: COMPARATOR
Intervention: Vehicle lotion
Number of subjects: 6
Study 11069515 — intervention group
Group type: COMPARATOR
Intervention: Topical ALA lotion (5%, 10%, 20%) vs. Vehicle lotion
Number of subjects: 6
Study 11069515 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo fluorescence spectroscopy
Number of subjects: 6
Study 11069515 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence microscopy
Number of subjects: 6
Study 8690823 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 14
Study 8690823 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine XL
Number of subjects: 14
Study 1686814 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 1686814 — intervention group
Group type: COMPARATOR
Intervention: Idazoxan
Number of subjects: 0
Study 6303213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 10
Study 6303213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 10
Study 6303213 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 10
Study 30251622 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPWISE intervention (structured lifestyle education programme)
Number of subjects: 414
Study 30251622 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 414
Study 29461408 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.025%
Number of subjects: 60
Study 29461408 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 60
Study 27132697 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 7227
Study 24490841 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative neuromuscular training (INT) performed 2 times per week during the first approximately 15 minutes of each PE class
Number of subjects: 40
Study 24490841 — intervention group
Group type: COMPARATOR
Intervention: Traditional PE (Control group)
Number of subjects: 40
Study 22970150 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (5 × 10^8 CFUs daily for 2 months)
Number of subjects: 40
Study 22970150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20950882 — intervention group
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy (EBRT)
Number of subjects: 219
Study 20950882 — intervention group
Group type: COMPARATOR
Intervention: High dose-rate brachytherapy (HDRBT) alone
Number of subjects: 219
Study 17560678 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 35
Study 17560678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 15905011 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg alcohol
Number of subjects: 12
Study 15905011 — intervention group
Group type: COMPARATOR
Intervention: juice (placebo)
Number of subjects: 12
Study 12414400 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior ciliary sclerotomy
Number of subjects: 9
Study 12414400 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral eye)
Number of subjects: 9
Study 10614553 — intervention group
Group type: EXPERIMENTAL
Intervention: Gerontology education program (GEP)
Number of subjects: 169
Study 8579030 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg twice daily)
Number of subjects: 15
Study 8579030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1673284 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 330
Study 1673284 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 330
Study 1673284 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 330
Study 1673284 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 330
Study 1673284 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 330
Study 1673284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 6927281 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of moxalactam and cefazolin (10 mg/kg)
Number of subjects: 19
Study 6927281 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of moxalactam and cefazolin (10 mg/kg)
Number of subjects: 19
Study 31689835 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-anchored annular closure device (ACD)
Number of subjects: 554
Study 31689835 — intervention group
Group type: COMPARATOR
Intervention: Limited lumbar discectomy alone (Control)
Number of subjects: 554
Study 27696662 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC)
Number of subjects: 225
Study 27696662 — intervention group
Group type: COMPARATOR
Intervention: Sham-RIC (Control)
Number of subjects: 225
Study 25546368 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice‐weekly prophylaxis (20‐30 IU kg(‐1))
Number of subjects: 80
Study 25546368 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐times‐weekly prophylaxis (30‐40 IU kg(‐1))
Number of subjects: 80
Study 25546368 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined prophylaxis (twice‐weekly and 3‐times‐weekly)
Number of subjects: 80
Study 25546368 — intervention group
Group type: COMPARATOR
Intervention: On-demand treatment
Number of subjects: 80
Study 24203649 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine therapy (RIT)
Number of subjects: 0
Study 24203649 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithyroid drug therapy (ATD)
Number of subjects: 0
Study 22719910 — intervention group
Group type: EXPERIMENTAL
Intervention: Low meal Frequency (3 meals per day; LFr)
Number of subjects: 12
Study 22719910 — intervention group
Group type: COMPARATOR
Intervention: High meal Frequency (14 meals per day; HFr)
Number of subjects: 12
Study 19375093 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg esreboxetine
Number of subjects: 17
Study 19375093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 17302567 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin gastrointestinal therapeutic system (4 mg doxazosin)
Number of subjects: 117
Study 17302567 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (0.2 mg)
Number of subjects: 117
Study 15370731 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation technique (intensive repetition of movements, more than 100 repetitions a day for each of 5 kinds of movement, applied in two 2-week sessions)
Number of subjects: 24
Study 15370731 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation exercise
Number of subjects: 24
Study 11775644 — intervention group
Group type: EXPERIMENTAL
Intervention: Essaven gel (EG)
Number of subjects: 28
Study 11775644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28